If the brain trust can bring in substantial revenue on LymPro - or acquire an acquisition (as recently alluded to) that is cash flow positive and is already trading on the NASD, then I suspect the shareholder community along with the Street will give a standing applaud - I know I would. This would be synonymous with 'financial engineering' that would greatly alleviate the current strain on AMBS's papered financial structure.